Status:
COMPLETED
Comparison of Biphasic Human Insulin 30 With Biphasic Insulin Aspart in Subjects With Diabetes
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Diabetes Mellitus, Type 1
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This trial is conducted in Europe. The aim of this trial is to compare the glycaemic control of biphasic insulin aspart (BIAsp) 70 and/or BIAsp 50 with biphasic human insulin (BHI) 30 treatment.
Eligibility Criteria
Inclusion
- Type 1 or Type 2 diabetes
- Current treatment with BHI 30 twice daily as the only insulin therapy for at least 3 months, with or without combination with oral hypoglycaemic agents
- Body mass index (BMI) maximum 40.0 kg/m\^2
Exclusion
- History of drug or alcohol dependence
- Impaired hepatic function
- Impaired renal function
- Cardiac disease
- Proliferative retinopathy
- Total daily insulin dose at least 1.80 IU/kg
Key Trial Info
Start Date :
March 1 2000
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2001
Estimated Enrollment :
666 Patients enrolled
Trial Details
Trial ID
NCT01520818
Start Date
March 1 2000
End Date
April 1 2001
Last Update
January 4 2017
Active Locations (77)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Aalst, Belgium, 9300
2
Novo Nordisk Investigational Site
Brussels, Belgium, 1020
3
Novo Nordisk Investigational Site
Brussels, Belgium, 1090
4
Novo Nordisk Investigational Site
Edegem, Belgium, 2650